Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.64 |
| ▸ | HTR1A | P08908 | 10/20 | 0.63 |
| ▸ | HTR1D | P28221 | 9/20 | 0.63 |
| ▸ | HTR1B | P28222 | 8/20 | 0.63 |
| ▸ | HTR2C | P28335 | 4/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | HTR5A | P47898 | 3/20 | 0.60 |
| ▸ | HTR6 | P50406 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 6/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | HTR1E | P28566 | 2/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B | O95264 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765265 | 0.89 | HTR1A (0.64) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL10552982 | 0.88 | HTR1D (0.69) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL10577689 | 0.87 | HTR1A (0.60) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL2539336 | 0.86 | HTR7 (0.61) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| Water SCHEMBL10581586 | 0.86 | HTR1A (0.58) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL10552426 | 0.85 | HTR1D (0.62) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL10578720 | 0.85 | HTR1D (0.62) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL10578881 | 0.85 | CYP1A2 (0.58) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL10555975 | 0.84 | HTR1A (0.57) | HTR7HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL2541510 | 0.84 | HTR1A (0.63) | HTR7HTR1AHTR1DHTR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4839377-A | TREATMENT OF MIGRAINE | GLAXO GROUP LIMITED (GB) | 1989-06-13 | — | — | US | claimed |
| US-11897918-B2 | Compositions and methods to increase production | Seqirus UK Limited (GB) | 2024-02-13 | — | — | US | disclosed |
| EP-3131578-B1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | SEQIRUS UK LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| US-20200040040-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | NOVARTIS (CH) | 2020-02-06 | — | — | US | disclosed |
| CN-108697670-A | Serotonin 1B receptor stimulators for transplanting potentiality in reinforcement | 巴斯德研究院 | 2018-10-23 | — | — | CN | disclosed |
| CN-108348486-A | 5-hydroxytryptamine 1B receptor agonists as promoters for satellite cell self-renewal and/or differentiation | 巴斯德研究院 | 2018-07-31 | — | — | CN | disclosed |
| EP-3131578-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | Novartis AG (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20170044216-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | Seqirus UK Limited (GB) | 2017-02-16 | — | — | US | disclosed |
| WO-2015158927-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | NOVARTIS AG (CH) | 2015-10-22 | — | — | WO | disclosed |
| CN-103339109-B | Tetrahydroisoquinoline derivative | ASTELLAS PHARMA INC | 2015-04-29 | — | — | CN | disclosed |
| EP-1173168-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | Respiratorius AB (SE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0665887-B1 | HUMAN 5-HT 2? RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 1998-10-14 | — | — | EP | disclosed |
| EP-0861081-A1 | USE OF EPINASTINE IN THE TREATMENT OF PAIN | BOEHRINGER INGELHEIM KG (DE) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997017971-A1 | USE OF EPINASTINE IN THE TREATMENT OF PAIN | BOEHRINGER INGELHEIM KG (DE) | 1997-05-22 | — | — | WO | disclosed |
| EP-0665887-A1 | HUMAN 5-HT 2? RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 1995-08-09 | — | — | EP | disclosed |
| EP-0641386-A1 | HUMAN 5HT-1B RECEPTOR (SEROTONIN RECEPTOR), PROCESS FOR PREPARING THE SAME AND ITS USES | BASF Aktiengesellschaft (DE) | 1995-03-08 | — | — | EP | disclosed |
| WO-1995006117-A1 | HUMAN 5-HT2 RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 1995-03-02 | — | — | WO | disclosed |
| WO-1993023535-A1 | HUMAN 5HT-1B RECEPTOR (SEROTONIN RECEPTOR), PROCESS FOR PREPARING THE SAME AND ITS USES | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-25 | — | — | WO | disclosed |
| US-4839377-A | TREATMENT OF MIGRAINE | GLAXO GROUP LIMITED (GB) | 1989-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044216-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | MRPL21, CHLSN, MAX | HTR7 4072/4885HTR1A 4519/4885HTR1D 4618/4885 |
| US-20200040040-A1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | MRPL21, CHLSN, MAX | HTR7 4072/4885HTR1A 4519/4885HTR1D 4618/4885 |
| US-11897918-B2 | Compositions and methods to increase production | MRPL21, CHLSN, MAX | HTR7 4072/4885HTR1A 4519/4885HTR1D 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.